Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | NCK1 | P16333 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL411739 | 0.83 | CYP1A2 (0.57) | CYP1A2ALDH1A1NCK1BACE1CYP2A6 | |
| SCHEMBL28140555 | 0.76 | TYMS (0.35) | CYP1A2KDM4ERAB9ALMNA | |
| SCHEMBL7630593 | 0.75 | KDM4E (0.52) | ALDH1A1MEN1KMT2ATDP1KDM4E | |
| SCHEMBL208188 | 0.75 | F7 (0.38) | ALDH1A1BACE1CYP2A6KDM4E | |
| SCHEMBL1552052 | 0.75 | ESR2 (0.44) | CYP1A2ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL208135 | 0.75 | BACE1 (0.47) | CYP1A2ALDH1A1BACE1CYP2A6MEN1 | |
| SCHEMBL206393 | 0.75 | BACE1 (0.47) | CYP1A2ALDH1A1BACE1CYP2A6MEN1 | |
| SCHEMBL5748489 | 0.75 | CYP1A2 (0.42) | CYP1A2ALDH1A1CYP2A6MEN1KMT2A | |
| SCHEMBL315256 | 0.75 | NCF1 (0.51) | CYP1A2ALDH1A1CYP2A6NQO2MEN1 | |
| SCHEMBL2302785 | 0.75 | SCN10A (0.39) | ALDH1A1BACE1MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | claimed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | claimed |
| EP-4185564-A1 | TRICYCLIC HETEROCYCLES | Merck Patent GmbH (DE) | 2023-05-31 | — | — | EP | claimed |
| CN-116134016-A | Tricyclic heterocycles | 默克专利股份公司 | 2023-05-16 | — | — | CN | claimed |
| WO-2023078813-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | MERCK PATENT GMBH (DE) | 2023-05-11 | — | — | WO | claimed |
| EP-4146652-A1 | TRICYCLIC HETEROCYCLES USEFUL AS TEAD BINDERS | Merck Patent GmbH (DE) | 2023-03-15 | — | — | EP | claimed |
| CN-115515959-A | Tricyclic heterocycles as TEAD binders | 默克专利股份公司 | 2022-12-23 | — | — | CN | claimed |
| WO-2021224291-A1 | TRICYCLIC HETEROCYCLES USEFUL AS TEAD BINDERS | MERCK PATENT GMBH (DE) | 2021-11-11 | — | — | WO | claimed |
| EP-2148859-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | Amira Pharmaceuticals, Inc. (US) | 2010-02-03 | — | — | EP | claimed |
| EP-2144875-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | Amira Pharmaceuticals, Inc. (US) | 2010-01-20 | — | — | EP | claimed |
| WO-2008137805-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | claimed |
| WO-2008137609-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | claimed |
| US-20070244128-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | US | claimed |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | US | claimed |
| US-5378711-A | α-arylacrylates substituted by a heterocyclic radical, and fungicides which contain these compounds | BASF AKTIENGESELLSCHAFT (DE) | 1995-01-03 | — | — | US | claimed |
| EP-4334319-A1 | 2,8-DIHYDROPYRAZOLO[3,4-B]INDOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Merck Patent GmbH (DE) | 2024-03-13 | — | — | EP | disclosed |
| CN-117616028-A | 2, 8-dihydropyrazolo [3,4-B ] indole derivatives for the treatment of cancer | 默克专利股份公司 | 2024-02-27 | — | — | CN | disclosed |
| EP-0490224-A2 | Derivatives of salicylic aldehyde and salicylic acid, sulfphuranalogs thereof, process and intermediates for their preparation | BASF Aktiengesellschaft (DE) | 1992-06-17 | — | — | EP | disclosed |
| US-4555472-A | OPTICAL RECORDING MEDIA | CANON KABUSHIKI KAISHA (JP) | 1985-11-26 | — | — | US | disclosed |
| US-4327213-A | ANTIULCER AGENTS | ACF Chemiefarma VA (NL) | 1982-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | YAP1, TERF2IP, TEAD1 | CYP1A2 4102/4885ALDH1A1 3813/4885NCK1 876/4885 |
| US-20070244128-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | CYP1A2 1193/4885ALDH1A1 1358/4885NCK1 2989/4885 |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | CYP1A2 1193/4885ALDH1A1 1358/4885NCK1 2989/4885 |
| US-20230174538-A1 | Tricyclic heterocycles | YAP1, TEAD1, TERF2IP | CYP1A2 3905/4885ALDH1A1 3857/4885NCK1 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.